No Data
Henlius (02696.HK): The application for a 1b/2 phase clinical trial for the injection of HLX43 (targeting PD-L1 antibody - new DNA topoisomerase I inhibitor conjugate) as a monotherapy or in combination therapy for advanced/metastatic solid tumors has bee
Gracell announced on December 4th that Henlius (02696.HK) recently received approval from the National Medical Products Administration (NMPA) for the application of HLX43 (a PD-L1 targeting antibody - a novel DNA topoisomerase I inhibitor conjugate drug) for monotherapy or combination therapy in phase 1b/2 clinical trials for advanced/metastatic solid tumors. The company plans to conduct clinical trials of the product for the relevant indications in China (excluding Hong Kong, Macao, and Taiwan) once the conditions are met. HLX43 was obtained by the company from Yilian Biomedical in Suzhou in November 2022.
Fosun Pharma (02196): Henlius has received approval from the National Medical Products Administration to conduct clinical trials for HLX22 in combination with trastuzumab and chemotherapy or trastuzumab in combination with chemotherapy for HER2-expressing
Fosun Pharma (02196) announced that its controlled subsidiary Henlius Biotech Co., Ltd. and...
Henlius (02696): The application for marketing approval of HLX11 (recombinant anti-HER2 domain II humanized monoclonal antibody injection) a biosimilar to pertuzumab, has been accepted by the National Medical Products Administration.
Henlius (02696) issued an announcement stating that recently, the company's independently developed biosimilar of patritumab, HLX11...
Shanghai Henlius Biotech Plans Key Shareholder Meeting
Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial
Fosun Pharma (02196.HK) subsidiary obtained pharmaceutical registration approval.
On December 3, Gelonghui reported that fosun pharma (02196.HK) announced that shanghai fosun pharma (Group) Co., Ltd. (hereinafter referred to as "the company") and shanghai henlius biotechnology Co., Ltd. and its holding subsidiaries (hereinafter collectively referred to as "henlius") have developed the Hanshuang (i.e., Shruvalumab injection, hereinafter referred to as "the pharmaceutical") combined with pemetrexed and carboplatin for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative that cannot be surgically removed.
